trial · primary record
CTX112
SLE (Systemic Lupus)
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 80 |
| Primary completion | 2031-12-31 |
| Primary endpoint | To evaluate the safety of CTX112 in adult subjects with refractory autoimmune diseases, including SLE, SSc or IIM |
| Registry ID | NCT06925542 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:33:10.909Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06925542
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.